Host defense against pathogens, pollutants, and cigarette smoke is dependent on an intact, functioning epithelium. In patients with emphysema, a loss of alveolar structure is associated with increased apoptosis of both epithelial and endothelial cells and decreased lung parenchyma VEGF and VEGFR-2 (Kasahara et al., 2001 ). In addition our laboratory has previously reported that inactivation of the pulmonary VEGF gene, through airway delivery of a cre recombinase adenoassociated virus (AAV/Cre) to VEGFLoxP mice, reproduces this increase in caspase-3 associated lung cell apoptosis accompanied by a reduction of VEGFR-2 and compromised integrity of the alveolar-capillary barrier (Tang et al., 2004) . Alveolar type II cells express high levels of VEGF as well as VEGF receptors (Ng et al., 2001) . Thus, this cell type may be important for both producing VEGF and responding to an injury or insult such as cigarette smoke by actively regulating the alveolar epithelium through VEGF signaling.
Type II cells produce surfactant. Alveolar surfactant is well known to lower surface tension at the air-liquid interface and contribute to a protective barrier. In addition, two hydrophilic proteins associated with surfactant, SP-A and SP-D, provide a specific role in the pulmonary innate immune system through their ability to recognize and participate in the phagocytosis of bacteria, apoptotic cells, and DNA by alveolar macrophages and epithelial cells (Vandivier et al., 2002; Pastva et al., 2007) . The critical role of surfactant is supported by targeted gene deletion studies in mice which reveal emphysema-like changes in airspace size and inflammatory cell influx following gene inactivation of several components of the alveolar surfactant system (SP-D, SP-C, PL A2 , ABCA1) (Rice et al., 1988; Botas et al., 1998; Korfhagen et al., 1998; Wert et al., 2000; Glasser et al., 2003; Bates et al., 2005) .
Thus, we hypothesized that in adult mice VEGF plays an important role in regulating surfactant homeostasis. Alterations in the surfactant system, in particular reductions in the surfactant associated pulmonary collectins, SP-A and SP-D, were hypothesized to weaken the innate immune system. In this study lung-targeted VEGF-deficient mice were challenged with a bioluminescent strain of Pseudomonas aeruginosa (PAO1-Lux) and pulmonary levels monitored by optical imaging.
VEGF-dependent type II cell function was determined in vivo by measuring several components and regulators of the surfactant system. In vitro a direct role of VEGF was tested by inactivating the gene in isolated adult VEGFLoxP type II cells and measuring surfactant homeostasis and apoptosis.
Materials and Methods

Animals
The Animal Subjects Committee of University of California, San Diego, approved the animal protocol for this study. The VEGFLoxP mouse strain was engineered by Dr. Ferrara's laboratory at Genentech, South San Francisco, CA (Gerber et al., 1999) . Male and female mice (age 8-12 weeks) were delivered either AAV/LacZ (control) or AAV/Cre to inactivate the gene and mice were challenged 5 weeks later with PAO1. There was no change in body weight or BAL fluid volume, protein concentration or cell number following VEGF gene inactivation (Supplementary Table 1 ).
Preparation of recombinant Cre recombinase expressing virus
For in vitro gene deletion experiments: recombinant adenovirus (Adv) expressing Cre recombinase or LacZ were produced and quantified. Recombinant adenoviruses were constructed using an adenovirus-5 backbone with protein-E1 deletion (Wang et al., 1996) . The inserted gene cassette contained a CMV promoter, cre recombinase or LacZ reading frame, and SV40 poly A. Adv/Cre and Adv/LacZ were packaged in 293 cells and purified by cesium chloride density centrifugation. Viral titers were estimated by determining the number of plaque forming units (pfu) in NIH3T3 cells infected with serial dilutions of adenovirus preparations. For the in vivo lung-targeted VEGF gene deletion experiment: recombinant adeno-associated virus (AAV) which express either LacZ or Cre recombinase coding regions were prepared as previously described (Tang et al., 2004) . Anesthetized VEGFLoxP mice were instilled via the trachea with 100 ml of AAV/Cre or AAV/ LacZ solution ($2 Â 10 10 total viral particles) followed immediately with a 200-ml bolus of perflubron (Rimar 101, Miteni, Tissino, Italy). At 5 weeks post-AAV infection, mice were either sacrificed or challenged with PAO1. Based on our previously published results this time point is associated with decreased levels of VEGF and VEGFR-2, increased septal wall cell apoptosis, alveolar damage and loss of lung elastic recoil (Tang et al., 2004) .
PAO1 infection and optical imaging
A bioluminescent reporter P. aeruginosa PAO1 Pgem-Lux was created by inserting a luxCDABE gene cassette under the control of the gentamicin resistance gene promoter into a single attTn7 intergenic site within the bacterial chromosome according to the method of Choi et al. (2005) . This strain constitutively expresses the lux gene cassette and does not have an altered PAO1 phenotype based on characteristic growth, motility, biofilm formation, and virulence against lettuce (unpublished data). Tracheal delivery of PAO1 Pgem-Lux [$2 Â 10 5 colony forming units (CFU)/30 ml/mouse] was accomplished by anesthetizing mice with ketamine:xylazine (100 mg:10 mg), making a small incision above the trachea and directly injecting the bacterial suspension just above the carina. Post-inoculation, mice were anesthetized with isoflurane and imaged using the Spectrum In Vivo Imaging System (IVIS) from Caliper Life Sciences. Bioluminescent PAO1 was quantified from images captured over 15 sec.
VEGF, TNFa and IL-6 ELISA VEGF and cytokine levels in type II cells and/or lung homogenates were measured by mouse specific ELISA's (R&D, Minneapolis, MN and Endogen, part of ThermoScientific, Rockford, IL).
Pulmonary type II cell isolation and VEGF gene inactivation
Type II pneumocytes were isolated from VEGFLoxP mice according to the method of Dobbs et al. (1986) . Cells were panned over culture dishes coated with anti-CD-32 and anti-CD-45 biotin labeled antibodies (AbCam, Cambridge, MA) plus strepavidin coated magnetic beads (Becton Dickenson, Franklin Lakes, NJ) and cultured on rat type I collagen dishes (4 mg/ml coating solution, Becton Dickenson). Type II pneumocyte purity was greater than 95% according to anti-lamellar body protein ABCA3 immunohistochemical analysis (Covance, Berkeley, CA). VEGF gene inactivation was accomplished in vitro by incubation of type II cells with 5-10 pfu/cell of Adv/Cre and compared to cells infected with a control virus, Adv/LacZ or untreated cells.
Surfactant measurements
Total phospholipids (PL) and disaturated phosphatidylcholine (DSPC). Total lipids from type II cells, lung tissue or cell-free bronchoalveolar lavage fluid (BALF) were extracted with chloroform/methanol according to the method of Bligh and Dyer (1959) . Disaturated phosphatidylcholine (DSPC) was further isolated by reaction with osmium tetroxide dissolved in carbon tetrachloride and passage over a column of neutral alumina (Alltech, Deerfield, IL) (Mason et al., 1976) . Total phospholipids (TPL) and DSPC were measured by phosphorus assay (Rouser et al., 1970) and expressed as nmol/mg protein. BALF cells, isolated after a 150g centrifugation spin, were re-suspended in 1 ml of saline, stained with trypan blue and counted in a hemocytometer. Total protein was measured in the cellfree BALF by the Bio-Rad DC Protein Assay using bovine serum albumin as a standard (Bio-Rad, Hercules, CA; Supplementary Spragg and Li (2000) . At the end of the 3 h labeling period, cells were again washed 3Â with DMEM and incubated for an additional 2 h in DMEM without radiolabel. Cells were collected and assayed for DSPC levels and the level for (Scott, 1994) . The DSPC fraction was isolated from both media and cell layers and the level of radioactivity determined by scintillation counting. The data are expressed as DSPC dpms (media)/DSPC dpms (media þ cells).
Alveolar phospholipid composition. Alveolar surfactant phospholipid composition was determined by measuring phosphorous levels following separation by thin layer chromatography (TLC). Phospholipids from 2 ml aliquots of cell-free BALF were extracted with chloroform-methanol (Bligh and Dyer, 1959) . Each extract was dried under nitrogen, re-suspended in chloroform, and separated on a silica gel TLC plate using triethylamine-ethanol-chloroform-distilled water (35:34:30:8) as the solvent (model LK5D, Whatman, Clifton, NJ). Phospholipid standards (Avanti Polar Lipids, Alabaster, AL) were run on the same plate and detected with Molybdenum Blue Phosphorous Spray (Sigma, St. Louis, MO). The separated BALF phospholipids were quantified using the Rouser phosphorus assay as described earlier (Rouser et al., 1970) .
Real time RT-PCR
Total cellular RNA was isolated from lung parenchyma using Tripure Isolation Reagent (Roche Molecular Biochemicals, Indianapolis, IN) followed by further purification over RNeasy Mini Kit columns including DNase I treatment (Qiagen Inc., Valencia, CA). RNA quantity and purity was determined by spectrophotometer and confirmed by formaldehyde-agarose electrophoresis. Three-hundred nanograms of total RNA was reversed transcribed using the Thermoscript RT-PCR System (Invitrogen Corp., Carlsbad, CA). The RT product was amplified in a reaction volume containing 2X SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA), HPLC purified forward and reverse primers (Supplementary Table 2 ) and the reference dye, ROX. Reactions were run on a MX3000P Real-Time PCR System (Stratagene, La Jolla, CA) at 958C, 10 min, 40 cycles of 958C, 30 sec; 558C, 60 sec; and 728C for 30 sec, followed by a 30 min dissociation curve to check for product purity. Relative mRNA levels were quantified and normalized to GAPDH using the 2DDC t method.
Western blot analysis
Surfactant-associated proteins and lipid transport regulatory proteins, ABCA1, ABCA3, and Rab3D, were measured in type II cells, BALF and lung tissue by Western blot. Type II cell protein extracts were prepared by freeze-thaw in lysis buffer [50 mM Tris, 150 mM NaCl, 0.5% Triton X-100 plus a Complete Protease Inhibitor Cocktail Tablet plus EDTA (Roche Diagnostics, Mannheim, Germany)]. Lung tissue was homogenized in 2 ml of homogenization buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1% Triton-X-100, complete protease inhibitor tablet with EDTA). Cell protein extracts (50 mg), BALF volume (15 ml) or lung homogenate protein (100 mg) were electrophoresed on a 15% SDS-PAGE gel. SP-A and SP-D were electrophoresed under reducing conditions. SP-B was analyzed under non-reducing conditions. For type II cells blots were incubated with polyclonal rabbit primary antibodies specific for SP-A, SP-B, Pro-SP-C, SP-D (Santa Cruz Biotech, Santa Cruz, CA) at dilutions of 1:500. For Western blot analysis of BALF and lung homogenates, rabbit anti-sheep SP-A and rabbit anti-rat SP-D antibodies, which cross react with mouse antigens and have a high specificity for detection of tissue samples, were used. These antibodies were generously given to us by Dr. Jo Rae Wright, Duke University Medical Center, NC. Lipid transporter molecules for all samples were detected with anti-ABCA1 (Novus, Littleton, CO), anti-ABCA3 (Covance, Berkeley, CA) or anti-Rab3D (Abcam, Cambridge, MA). Signals were detected with an HRP conjugated anti-IgG secondary antibody and detected by chemiluminesence using an ECL Kit (Amersham, Piscataway, NJ). Densitometry was performed with Gel Pro Analyzer software (Mediacybernetics, Silver Springs, MD).
Type II cell apoptotic index
Type II cells were fixed with 2% paraformaldehyde and the number of TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling) positive nuclei detected using an In Situ Cell Death Detection Kit, POD (Roche Applied Science, Indianapolis, IN). TUNEL positive nuclei were identified by light microscope and expressed as the number of positive nuclei per 100 total nuclei in 10 randomly selected fields per culture dish in three separate cultures/ experimental group.
Statistical analyses
The probability of a significant difference between control (uninfected), Adv/LacZ, and Adv/Cre infected type II cell cultures was calculated using a one-way ANOVA and Tukey post-hoc tests for individual differences. An unpaired Student's t-test was used to determine differences in PAO-lux, cell number, phospholipid content, and gene expression between mouse lungs infected with AAV/LacZ or AAV/Cre. Data were expressed as mean AE SEM and P < 0.05 was considered significant.
Results
In vivo detection of bioluminescent P. aeruginosa (PAO1-Lux) in VEGF gene inactivated lungs
In VEGFLoxP mice instilled with AAV/Cre, lung homogenate VEGF levels were reduced by 57% at 5 weeks compared to mice instilled with AAV/LacZ (Fig. 1A) . At this post-AAV time point, mice were instilled with PAO1-Lux and imaged in vivo. At 6 h there was no difference in the amount of PAO1-Lux detected in the lungs of AAV/Cre infected mice compared to the AAV/LacZ group (LacZ 1.6 AE 0.5 Â 10 5 ; Cre 1.3 AE 0.4 Â 10 5 ). Twenty-four hours later pulmonary PAO1-Lux levels were increased in both mouse groups but were 3.25-fold higher in the AAV/Cre group compared to LacZ (LacZ 4.9 AE 1.5 Â 10 6 , Cre 1.6 AE 0.5 Â 10 7 , P ¼ 0.046; Fig. 2 ). PAO1-Lux was detected in liver isolated at 24 h in 5 out of 13 LacZ mice and 5 out of 16 Cre mice. PAO1-Lux was not detected in blood samples.
Cytokines
Comparison of inflammatory cytokines in the AAV/LacZ and AAV/Cre groups, both challenged with PAO1-Lux, revealed increased lung levels of IL-6 (LacZ 366 AE 93 pg/mg, Cre 1013 AE 140 pg/mg, P ¼ 0.01) and TNFa (LacZ 86 AE 10 pg/mg, Cre 382 AE 39 pg/mg, P ¼ 0.04) in the VEGF gene inactivated lungs compared to controls (Fig. 3) . Lungs from both AAV/LacZ and AAV/Cre groups challenged with PAO1-Lux contained numerous neutrophils (Supplementary Fig. 2) . In vivo: SP-D levels from lung BALF (Fig. 4A ) and tissue homogenates (Fig. 4B ) before PAO1 challenge were reduced by 54% in BALF ( P < 0.05) and by 53% ( P < 0.05) in lung tissue in VEGF-deficient lungs compared to the AAV/LacZ group (Fig. 4C,D) . No significant differences between AAV/Cre and AAV/LacZ lungs were detected for SP-A or SP-B (Fig. 4A-D) . SP mRNA levels measured in lung homogenates revealed a 56% ( P < 0.05) lower SP-D mRNA level in VEGF-deficient lungs (Fig. 4H) .
In vitro: Type II cells, isolated from adult VEGFLoxP mice revealed a 69% decrease ( P ¼ 0.014) in VEGF by day 2 postAdv/Cre infection compared to uninfected or Adv/LacZinfected cells. VEGF levels were further reduced to 20% of the control values ( P ¼ 0.0024) on day 3 and remained decreased at 23% of control values ( P ¼ 0.0002 and P ¼ 0.0003) on days 4 and 5 (Fig. 1B) . Western analysis of cellular extracts from VEGFinactivated and control type II cultures revealed a 58% ( P ¼ 0.015) decrease in SP-B levels and a 46% ( P ¼ 0.008) decrease in SP-D levels by Western analysis compared to uninfected and Adv/LacZ infected cultures (Fig. 4I,K,M) . SP-A and pro-SP-C were not different between the cell culture groups (Fig. 4I,J,L) .
Surfactant phospholipids in VEGF-inactivated lung and cultured type II cells
In vivo: Alveolar surfactant levels, assessed by measuring phospholipids in BALF and total DSPC levels in lung homogenates, were not altered at 5 weeks post-AAV/Cre delivery compared to AAV/LacZ lungs (Fig. 5A,B) . Further analysis of the alveolar phospholipid composition by thin layer chromatography revealed a 23% decrease in the sphingomyelin fraction in AAV/Cre-infected lungs compared to control AAV/ LacZ lungs (Table 1 , P ¼ 0.029).
In vitro: Three days post Adv/Cre infection, type II cells revealed a 33% ( P ¼ 0.041) decrease in total phospholipid levels and a 45% ( P ¼ 0.023) decrease in DSPC levels compared to uninfected and Adv/LacZ-infected control cells (Fig. 5C ). Newly synthesized DSPC decreased by 62% ( P ¼ 0.007) after VEGF inactivation (Fig. 5D) . However, when VEGF-deficient type II cells were stimulated to secrete surfactant with TPA, DSPC secreted into the cell media was increased by 55% ( P ¼ 0.031) compared to uninfected or Adv/LacZ infected control cells (Fig. 5E ).
Lipid transport regulators in VEGF deficient lungs and cultured type II cells
In vivo: 5 weeks post infection, ABCA1 mRNA and protein levels and Rab3D mRNA levels were similar in AAV/Cre and AAV/ LacZ infected lungs (Fig. 6A-D) . However, Rab3D protein 
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levels were significantly decreased in AAV/Cre infected lungs compared to AAV/LacZ infected lungs (Fig. 6E,F) . Type II cell and lamellar body morphology appeared normal ( Supplementary Fig. 2 ). In vitro: In VEGF-deficient type II cells, ABCA1 protein levels decreased by 64% ( P ¼ 0.02) and Rab3D protein levels decreased by 41% ( P ¼ 0.03) compared to the control groups (Fig. 6G-I ). ABCA3 protein levels were unaltered in Adv/Cre infected type II cells (Fig. 6G,J) .
Apoptosis in VEGF-deficient type II cells
In vivo: CTP:phosphocholine cytidylyltransferase (CCT) mRNA was decreased by 48% in VEGF-deficient lungs at 5 weeks postinfection compared to AAV/LacZ lungs ( P < 0.05) (Fig. 7A) . In vitro: TUNEL-positive apoptotic type II cell number was increased 4.2-fold ( P ¼ 0.003) in VEGF-deficient cells compared to control groups (Fig. 7B) .
Discussion
Our laboratory, as well as others, has previously shown that maintaining adequate pulmonary VEGF or VEGFR-2 signaling is essential for preserving an intact alveolar-capillary structure (Kasahara et al., 2000; Tang et al., 2004) . The aim of the present study was to determine whether adult type II cells, which express high levels of VEGF, VEGFR-1, and VEGFR-2, also regulate surfactant homeostasis and innate immunity through a VEGF-dependent pathway (Fehrenbach et al., 1999) . The primary findings of this study are (1) while VEGF has the potential to regulate surfactant homeostasis in isolated type II cells, compensatory mechanisms exist in vivo to ensure that both the normal amount and composition of surfactant lipids are maintained on the alveolar surface. (2) However, decreased pulmonary VEGF expression in vivo results in the down regulation of the surfactant associated pulmonary collectin, SP-D, and a compromised defense against P. aeruginosa.
VEGF has the potential to regulate the production of surfactant by type II cells Inhibiting VEGF expression by 80% in isolated type II cells resulted in a decrease in total phospholipids and the level of mature disaturated phosphatidylcholine (DSPC) found in surfactant. Interestingly, while DSPC synthesis was down regulated, secretion of DSPC in response to TPA was augmented. This later observation suggests that signaling mechanisms were still present to localize surfactant lipids to the extracellular space under the appropriate conditions. In vivo increased stretch or mechanical tension in an over inflated emphysema-like lung may provide the signal (Wirtz and Dobbs, 1990) . In addition several lipid trafficking molecules were down regulated including the intracellular hydrophobic surfactant associated protein, SP-B, the reverse transporter, ABCA1, and a GTPase involved in exocytosis of surfactant lipids, Rab3D. The extracellular hydrophilic surfactant associate protein SP-D was decreased by 50% in VEGF gene inactivated type II cells. One of the functions of SP-D is to regulate the reuptake of lipid aggregates that are recycled and reorganized into surfactant within type II cells .
Alveolar surfactant is preserved in vivo
In contrast to the down regulation of surfactant lipids in isolated type II cells, a 57% reduction in pulmonary cell VEGF in vivo was not associated with altered alveolar or tissue DSPC levels. This maintenance of surfactant lipids occurred despite a decrease in CCT mRNA and SP-D expression. CCT is the rate-limiting enzyme for phosphatidyl choline synthesis. However, not all phosphatidyl choline is converted to the mature disaturated recovered from VEGFLoxP mice instilled 5 weeks prior with either AAV/LacZ (LacZ; n U 7) or AAV/Cre recombinase virus (Cre; n U 7). B: Unaltered tissue surfactant lipids. The levels of tissue associated surfactant phospholipids, measured as disaturated phosphatidylcholine (DSPC), were also similar in the experimental Cre group (n U 7) and the control LacZ group (n U 7). C: VEGF gene inactivation resulted in a decrease in total PL and DSPC levels. Reduced VEGF expression 72 h post-Adv/Cre infection (Cre) was accompanied by a decrease in type II cell total phospholipid (PL) and disaturated phosphatidylcholine (Sat-PC) levels compared to both uninfected cells (Con) and Adv/LacZ infected cultures (Adv/LacZ) n U 6 cultures, M significant difference from the uninfected control group (Con) P < 0.05. D: Decreased DSPC synthesis in VEGF-deficient type II cells.
3 H choline incorporation into the DSPC fraction. Values represent the mean W SD, n U 6 type II cell cultures. 
Results represent the percent of total isolated phospholipids (PL).
Values are the mean þ SE, n ¼ mice 4. Ã P < 0.05.
form and organized into surfactant. Phosphatidyl choline is also a major component of membrane lipids and a decrease in CCT expression can be indicative of ongoing apoptosis (Henderson et al., 2006) . SP-D also has several cellular functions, but its specific role in surfactant homeostasis, as mentioned above, is to facilitate the reuptake of surfactant lipid aggregates that are recycled and reorganized into mature surfactant. In SP-D (À/À) null mice surfactant lipids accumulate in numerous foamy, multinucleated macrophages and hyperplasic type II cells with large lamellar bodies. However, heterozygous SP-D (þ/À) mice do not display any obvious phenotypic abnormalities or accumulate lipid despite approximately 50% less SP-D (Botas et al., 1998; Korfhagen et al., 1998) . Thus, our observation of unaltered surfactant lipid levels in lung-targeted VEGF inactivated mice, with 50% less SP-D, is consistent with the response in heterozygous SP-D (þ/À) mice. Taken together with the data collected in our in vitro system, the results from this in vivo model of pulmonary VEGF gene inactivation suggest cell-cell interactions and/or signals generated in an in vivo environment compensate for reduced pulmonary VEGF expression and maintain alveolar surfactant levels (Tang et al., 2004) .
Potential compensatory mechanism for maintaining alveolar surfactant
There are several possible mechanisms that may account for the differences in surfactant lipid levels in VEGF gene ablated cultured type II cells and pulmonary cells in vivo.
(1) Adaptive changes in the reuptake and/or secretion of surfactant lipids in lung cells targeted in vivo may allow alveolar surfactant levels to be restored over a longer 5-week period than the 3 days type II cells were cultured in vitro. A reduced reuptake compensatory mechanism has been demonstrated in the lungs of transgenic mice that chronically over express TNF-a. In contrast acute TNF-a treatment of lungs or type II cells decreases phosphatidylcholine synthesis and increases secretion. This latter response to acute TNF-a is similar to the decreased DSPC synthesis and increased secretion in VEGF-deficient isolated type II cells (Salome et al., 2000; Carroll et al., 2002) . (2) Another possible in vivo compensatory mechanism may involve the interaction of type II cells with other pulmonary phagocytes. Phagocytosis of phosphatidyl serine presenting apoptotic cells by macrophages interacting with the remaining 50% SP-D, or other lung collectins (C1q or SP-A), and calreticlin/CD91 may be sufficient to increase or maintain ABCA1 levels, and allow ABCA1-selective efflux of unsaturated phospholipids and cholesterol from engulfed apoptotic cells while at the same time salvaging saturated PC for incorporation into surfactant (Gardai et al., 2003; Zhou et al., 2004) . (3) The one minor surfactant lipid component that was altered in VEGF-deficient lungs was sphingomyelin. The observed 23% decrease in sphingomyelin suggests that it has been hydrolyzed by sphingomyelinases to ceramide and sphinogsine, and these sphingomyelin breakdown products have been reported to inhibit CCT expression and activity, stimulate caspase-3 dependent apoptosis, decrease apoptotic cell clearance and increase ABCA1 levels, (Baburina and Jackowski, 1998; Lagace et al., 2002; Witting et al., 2003; Petrache et al., 2005; Filosto et al., 2011; Petrusca et al., 2010) . The finding that ABCA1 was down regulated in isolated type II cells but maintained in our in vivo model also supports a possible mechanism in which sphingomyelin-induced ABCA1 plays a role in recycling DSPC from phagocytosed apoptotic cells. More experiments will be needed to verify and elucidate the steps involved in potential compensatory pathways for preserving alveolar surfactant in vivo.
Maintenance of alveolar surfactant at the cost of inefficient efferocytosis
Consistent in both the in vitro and in vivo VEGF inactivation models was a decrease in SP-D and ongoing apoptosis (Tang et 
al., 2004
). Decreased levels of CCT mRNA, sphingomyelin and Rab3D in VEGF deficient lungs also indicate persistent or ongoing apoptosis (Baburina and Jackowski, 1998; Vandivier et al., 2002; Cartel and Post, 2005; Petrache et al., 2005) . However, in vivo decreases in both VEGF and SP-D might suggest not only an increase in the number of cells undergoing apoptosis but also a delay in the clearance of apoptotic cells. In a study by Vandivier et al. (2002) comparing SP-D, C1q and SP-A in naïve mouse lungs, SP-D was the most efficient in vivo pulmonary collectin for the recognition and uptake of apoptotic cells by resident macrophages. Furthermore, enhancing the expression of VEGF in the lung promotes the clearance of apoptotic cells by alveolar macrophages (Kearns et al., 2012) .
VEGF-dependent clearance of P. aeurginosa
Unresolved apoptosis and lower levels of the innate immune molecule, SP-D, are also potential factors in the ability to efficiently clear bacteria from the lung. In this study, we have demonstrated that an SP-D recognized pathogen, P. aeruginosa, accumulates in VEGF-deficient mouse lungs and signals amplified IL-6 and TNFa responses. Previous studies have reported SP-D can recognize and stimulate the phagocytosis of P. aeruginosa by alveolar macrophages (Restrepo et al., 1999) as well as enhance clearance in vivo (Giannoni et al., 2006) . In addition to poor phagocytosis, SP-D null mice infected with group B streptococcus or Haemophilus influenzae demonstrate increased inflammatory cell recruitment and cytokine production . Likewise VEGF pre-treatment has been reported to reduce respiratory syncytial virus replication in neonatal lambs in part by maintaining SP-D levels and attenuating neutrophil recruitment (Meyerholz et al., 2007) . In the present study, P. aeruginosa infection in VEGF inhibited mice led to enhanced inflammatory cytokines, IL-6, and TNFa, but neutrophil recruitment was unaffected. Furthermore, P. aeruginosa (PAO1) levels did not differ early (6 h) after infection. This observation would suggest that altered lung mechanics due to an emphysema-like lung structure is not likely to be a major factor. However, less available SP-D, due to decreased expression, as well as competition with an abundance of apoptotic cells, would suggest that innate immune mechanisms to defend against and/ or clear PAO1 and possibly other SP-D recognized bacteria are compromised.
Conclusion
VEGF has the potential to regulate type II cell function in the adult murine lung. Inhibition of VEGF expression in isolated adult type II cells leads to increased apoptosis and decreases in surfactant lipid and expression of SP-B and SP-D (Clark et al., 1995; Wang et al., 2007) . However, in vivo alveolar surfactant lipid and associated proteins are preserved with the exception of SP-D. VEGF deficient lungs are more susceptible to an SP-D recognized bacteria, P. aeruginosa, and exhibit an exaggerated cytokine response. These observations suggest that VEGF may be important for maintaining an effective defense against certain types of bacteria and an inefficient VEGF-dependent mechanism could be an underlying factor in the prevalence of repeated bacterial infections that occur in several chronic lung diseases. 
